Fig. 4: Bmp2 and Bmp5 are upregulated upon treatment with anti-BMP1.3 antibody and exert cardioprotective activity.

a Quantification of the expression levels of Bmp2 and Bmp5 in primary cardiac fibroblasts and cardiomyocytes cultured in hypoxic conditions in the absence of treatment (control) or treated with anti-BMP1.3 antibody (5 µg/ml), normalized to Gapdh. b Quantification of the expression levels of Bmp2 and Bmp5 in the heart of mice subjected to MI in the absence of treatment (control) or after injection of anti-BMP1.3 antibody (150 µg/kg). c Representative images from tissue section of infarct area of untreated rats (control) or treated with anti-BMP1.3 antibody (150 µg/kg) stained with either anti-BMP2 or anti-BMP5 antibody (brown) and hematoxylin (violet) to visualize nuclei. d Quantification of living cardiomyocytes cultured in hypoxic conditions expressed as number of cardiomyocytes per field and exposed to the indicated enriched supernatants collected from CHO transfected with control plasmid (pGI) or plasmid for the overexpression of BMP2 and/or BMP5. e Representative images of rat neonatal cardiomyocytes cultured in hypoxic conditions and exposed to the indicated treatments. Cardiomyocytes were stained with anti-α-actinin antibody and nuclei with DAPI. f Quantification of living cardiomyocytes cultured in hypoxic conditions and exposed to the indicated treatments. g Representative images of rat neonatal cardiomyocytes cultured in hypoxic conditions in the absence of treatment (−Ab) or treated with anti-BMP1.3 antibody (+Ab) and transfected with the indicated siRNAs (mock = scramble siBMP5). Data in a, b, d and f are shown as mean ± s.e.m. Sample number is indicated inside or above each bar. Statistical significance was determined using unpaired, two-sided t-test in a, b or one-way ANOVA followed by Dunnet’s in d or Tukey’s multiple comparison test in f. Scale bar in c, e and g is 100 µm. Source data are provided as a Source Data file.